Chemotherapy-free triplet ‘sets new benchmark’ in follicular lymphoma

(MedPage Today) — ORLANDO — Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death…